Testing New Formats for the Presentation of Research Evidence to Health Care Managers and Policy Makers
5 de mayo de 2020 actualizado por: Unity Health Toronto
A Randomized Trial to Compare the Effects of a Novel Versus Traditional Systematic Review Format on the Ability of Health Care Managers and Policy Makers to Understand and Apply Evidence
The purpose of this project is to identify and use our knowledge on the barriers and facilitators to using systematic reviews (SR) by health care managers (HCM) and policy markers (PM) to develop and test a novel format for presentation of SR for HCM and PM.
We will invite HCM and PM from hospitals and regional authorities in Ontario, Alberta, and British Columbia to participate in a randomized-control trial.
Participants will receive a link to an online consent survey, and then be randomly allocated to receive access to a novel SR or its traditional presentation.
There is no time limit to completing the task, and participants are able to save their responses and finish later.
Participants are able to withdraw from the study by not completing the task.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
Despite advances in the conduct and reporting of traditional systematic reviews, current evidence suggests that they are used infrequently by health care managers and policy makers in decision making. Managers and policy makers have suggested that concise presentation positively affects the use of systematic reviews. The purpose of this randomized controlled trial is to assess the impact of a traditional systematic review format compared with the innovative format on the ability of health care managers and policy makers to understand the evidence in the review and apply it to a relevant health care decision making scenario.
The two end-user groups have different formatting needs and we will therefore run 2 parallel studies, randomizing each group separately. Once participants have consented to participate, a computer generated randomization process will allocate them to one of 2 arms (1:1 ratio). Participants will either receive either a traditional format or a novel format. Unequal block randomization will be used and allocation will be concealed through central assignment. Outcomes assessors will be blinded and participants will be blinded to the citation of the review so that the traditional version will not be easily accessible in its original format from the relevant journal.
This study will be the first study to engage health care managers and policy makers in the testing of formats for presentation of research evidence relevant to their needs. The results of the project will help increase the uptake of systematic review results in health care management policy decision-making, ultimately leading to informed decision making and positively impacting the health of Canadians.
Tipo de estudio
Intervencionista
Inscripción (Actual)
257
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Ontario
-
Toronto, Ontario, Canadá, M5B 1W8
- St. Michael's Hospital
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
Sí
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Health care managers from the Alberta SCNs, CAHO in Ontario, the RHAs and AQESSS in Quebec and RHAs from BC will be invited to participate.
- Policy makers/analysts from the Ontario, BC, Alberta and Quebec Ministries of Health
Exclusion Criteria:
- Health care managers or policy makers who are unwilling or unable to give informed consent.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Novel systematic review format
A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers.
Participants receiving the intervention will be asked to read and answer questions using a novel systematic review format.
|
A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers.
|
|
Sin intervención: Traditional systematic review format
Control participants will be asked to read and answer questions using a traditional systematic review format.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of participants (health care managers or policy makers) who appropriately consider and apply the evidence from each systematic review format
Periodo de tiempo: This measure will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
The proportion of participants (health care managers or policy makers) who appropriately consider and apply the evidence from each systematic review format to the scenario as measured by agreement with an expert panel's recommendation.
A panel of 4 health care managers or policy makers from our research team and 2 content experts.
Their answers will provide the definition of appropriate application of the evidence.
Two investigators who will be blind to allocation will independently determine if the participant's answer agrees with that from the expert panel.
Disagreements will be resolved by a third investigator, independently.
Agreement between investigators will be reported using the kappa statistic.
|
This measure will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Comprehension of the review
Periodo de tiempo: This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Comprehension of the review - defined as the proportion of participants (health care managers or policy makers) who accurately define the bottom line from the systematic review as defined by an expert panel.
A panel of 4 health care managers or policy makers from our research team and 2 content experts.
Their answers will provide the definition of the bottom line from the systematic review.
Two investigators who will be blind to allocation will independently determine if the participant's answer agrees with that from the expert panel.
Disagreements will be resolved by a third investigator, independently.
Agreement between investigators will be reported using the kappa statistic.
|
This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
|
Intention to use evidence
Periodo de tiempo: This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Intention to use evidence - collected through a 12-item likert scale survey.
The survey has good face validity amongst policy makers and managers.
The mean and SD of each item in the survey will be reported and we will provide a summary score of all items and convert it to a percentage.
|
This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
|
Perceived tentativeness of research findings
Periodo de tiempo: This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Perceived tentativeness of research findings - collected through a 6-item likert scale survey.
This has been pre-tested to make sure that the items are intelligible to people and to achieve high levels of face validity and reliability.
The mean and SD of each item in the survey will be reported and we will provide a summary score of all items and convert it to a percentage.
|
This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
|
Provisional opinion about the intervention
Periodo de tiempo: This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Provisional opinion about the intervention - collected through a 14-item likert scale survey.
This has been pre-tested to make sure that the items are intelligible to people and to achieve high levels of face validity and reliability.
The mean and SD of each item in the survey will be reported and we will provide a summary score of all items and convert it to a percentage.
|
This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Sharon e Straus, Unity Health Toronto
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
16 de mayo de 2017
Finalización primaria (Actual)
30 de noviembre de 2019
Finalización del estudio (Actual)
30 de noviembre de 2019
Fechas de registro del estudio
Enviado por primera vez
5 de enero de 2017
Primero enviado que cumplió con los criterios de control de calidad
1 de febrero de 2017
Publicado por primera vez (Estimar)
2 de febrero de 2017
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
7 de mayo de 2020
Última actualización enviada que cumplió con los criterios de control de calidad
5 de mayo de 2020
Última verificación
1 de mayo de 2020
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- SMH-312381
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .